About Durvalumab
            
            Class: | Monoclonal antibody (PD-L1 inhibitor)  
Use: | Treatment of unresectable stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed following platinum-based chemotherapy and radiation therapy; also indicated for the treatment of locally advanced or metastatic urothelial carcinoma.  
Adult dose: | 10 mg/kg administered intravenously every 2 weeks.  
Pediatric dose: | Safety and efficacy have not been established in pediatric patients; not recommended for us
         
        
            
                
                
                    
                        Drug Class
                    
                    Monoclonal antibody (PD-L1 inhibitor)
                 
                
                
                    
                        Uses & Indications
                    
                    Treatment of unresectable stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed following platinum-based chemotherapy and radiation therapy; also indicated for the treatment of locally advanced or metastatic urothelial carcinoma.
                 
                
                
                    
                        Storage Requirements
                    
                    Store in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: AstraZeneca UK Limited, UNITED KINGDOM
                    
                    
                    Package Size
                    2.4ml Vial
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 4292.50
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        10 mg/kg administered intravenously every 2 weeks.
                    
                    
                        Pediatric Dose
                    
                    
                        Safety and efficacy have not been established in pediatric patients; not recommended for use in this population.
                    
                 
                
                
                    
                        Side Effects
                    
                    Fatigue, nausea, decreased appetite, cough, dyspnea, rash, diarrhea, and infusion-related reactions.
                 
             
         
        
        
            
                Contraindications & Precautions
            
            History of severe hypersensitivity reactions to durvalumab or any component of the formulation; caution in patients with autoimmune diseases or those receiving immunosuppressive therapy.
         
        
        
            
                Important Warnings
            
            Immune-mediated adverse reactions may occur, including pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis. Monitor for signs and symptoms and manage accordingly. Discontinue therapy for severe reactions.
         
        
        
        
        
        
        
        
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.